Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.55 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PKLR | P30613 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084516 | 0.82 | MAPK14 (0.50) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL25343704 | 0.80 | MAPK14 (0.56) | MAPK14MAPKAPK2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4077227 | 0.75 | MAPK14 (0.61) | MAPK14CYP2D6CYP2C9CYP2C19MAPK13 | |
| SCHEMBL3978687 | 0.73 | MAPK14 (1.00) | MAPK14MAPKAPK2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1884315 | 0.68 | MAPK14 (0.57) | MAPK14MAPKAPK2PKMMAPK13RAF1 | |
| SCHEMBL3634976 | 0.68 | MAPK14 (0.62) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3767381 | 0.68 | MAPK14 (0.65) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3757488 | 0.68 | MAPK14 (0.65) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL13884432 | 0.68 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL1878359 | 0.66 | MAPK14 (0.47) | MAPK14MAPKAPK2PKMMAPK13RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080546-B2 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009055033-A1 | PYRAZOLO-PYRIDINONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | IL1B, IL1R1, IL1A | MAPK14 52/4885MAPKAPK2 41/4885PKM 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.